Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. — Investor Relations & Filings

Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2021-09-30 Board/Management Inform…
Country IN India
Listing BSE.NS LINCOLN

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
Board Meeting — Other business matters
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) informing about a scheduled Board of Directors meeting to consider issuing/allotting equity shares pursuant to a Scheme of Amalgamation approved by the National Company Law Tribunal. It references compliance with SEBI regulations and trading window closure related to unpublished price sensitive information. The document is dated September 30, 2021, and is an intimation under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content is an announcement of a board meeting and related corporate actions, not a full report or financial statement. The document length is 3206 characters, which is relatively short and consistent with a regulatory announcement. Therefore, this document fits best under the category of Board/Management Information (MANG), as it announces a board meeting and related corporate decisions.
2021-09-30 English
Shareholders meeting
Regulatory Filings
2021-09-30 English
Updates
Regulatory Filings
2021-09-21 English
Updates
Regulatory Filings Classification · 95% confidence The document is a press release announcing the approval by the National Company Law Tribunal (NCLT) of a scheme of amalgamation between Lincoln Parenteral Ltd and Lincoln Pharmaceuticals Ltd. It discusses the regulatory approval, the expected synergies, and business implications of the merger. There are no financial statements, detailed financial performance data, or management discussion of financial results. The document is primarily an official announcement of a corporate restructuring event, specifically the approval of an amalgamation scheme. This fits best under the category of a Regulatory Filing (RNS) as it is a general regulatory announcement related to corporate actions and does not fit into more specific categories like M&A filings (which are typically merger proxy statements or tender offer documents), nor is it a full merger filing or a financial report. The document length is about 9,147 characters, which is substantial but the content is clearly a media release and regulatory announcement rather than a detailed financial or merger filing document. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-09-16 English
Scheme of Arrangement
Regulatory Filings
2021-09-16 English
Copy of Newspaper Publication
Regulatory Filings
2021-09-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.